益气解毒通络颗粒对乙肝肝硬化肝星状细胞标记物PDGF-AB、PDGF-BB的影响
|
摘要
目的观察益气解毒通络颗粒剂治疗乙肝肝硬化好转的分子机制,完善该方治疗乙肝肝硬化的理论基础。方法随机选择我院体检中心体检健康者15例,肝炎门诊就诊的乙肝肝硬化患者42例,乙肝肝硬化患者均已规范使用抗病毒药恩替卡韦分散片治疗,入组后予益气解毒通络颗粒治疗6个月;对健康者,分别在乙肝肝硬化患者治疗前、治疗6个月后采集血样,待标本集中后采用酶联免疫吸附法成批检测血小板衍生生长因子-AB(PDGF-AB)、血小板衍生生长因子-BB(PDGF-BB)的含量。并将测定结果进行统计分析。结果结果显示,乙肝肝硬化患者血清PDGF-AB水平治疗前较健康者差异显著(<0.01),治疗后较治疗前有所升高(<0.05),但仍低于健康者(<0.05);乙肝肝硬化患者血清PDGF-BB水平治疗前及治疗后与健康者差异显著(<0.01),治疗后较治疗前有所升高,但无统计学意义(>0.05);与治疗前比较,肝功能改善效果明显(<0.05)。结论 PDGF-AB和PDGF-BB水平的变化与乙肝后肝硬化的发病相关,益气解毒通络颗粒能够改善乙肝肝硬化患者血清PDGF-AB和PDGF-BB水平,但对于PDGF-AB的影响更甚。
Objective To observe the molecular mechanism of Yiqi Jiedu Tongluo granules in treatment of post-hepatitis B liver cirrhosis and improve its theoretical basis. Methods 15 healthy persons and 42 patients with post-hepatitis B liver cirrhosis were chosen. The patients with post-hepatitis B liver cirrhosis had been treated by entecavir. Patients with hepatitis B cirrhosis were treated with antiviral drug entecavir dispersible tablets for 6 months, then treated with Yiqi Jiedu Tongluo granules for 6 months. The content of factor-AB(PDGF-AB) and platelet-derived growth factor-BB(PDGF-BB) and the results were statistically analyzed. Results The level of serum PDGF-AB was with significant difference between the patients with hepatitis B before treatment and healthy people(P<0.01), and increased after treatment(P<0.05), but still lower than that in healthy people(P<0.05); the levels of serum PDGF-BB in patients with hepatitis B cirrhosis before and after treatment were significantly lower than those in healthy people(P<0.01), and increased after treatment, but the increase was not statistically significant(P>0.05);compared with before treatment, there was significant difference in the improvement of liver function(P<0.01). Conclusion The changes of PDGF-AB and PDGF-BB levels are related to the occurrence of post-hepatitis B cirrhosis. Yiqi Jiedu Tongluo granules can improve the serum levels of PDGF-AB and PDGF-BB in patients with hepatitis B cirrhosis, especially on PDGF-AB.
Objective To observe the molecular mechanism of Yiqi Jiedu Tongluo granules in treatment of post-hepatitis B liver cirrhosis and improve its theoretical basis. Methods 15 healthy persons and 42 patients with post-hepatitis B liver cirrhosis were chosen. The patients with post-hepatitis B liver cirrhosis had been treated by entecavir. Patients with hepatitis B cirrhosis were treated with antiviral drug entecavir dispersible tablets for 6 months, then treated with Yiqi Jiedu Tongluo granules for 6 months. The content of factor-AB(PDGF-AB) and platelet-derived growth factor-BB(PDGF-BB) and the results were statistically analyzed. Results The level of serum PDGF-AB was with significant difference between the patients with hepatitis B before treatment and healthy people(P<0.01), and increased after treatment(P<0.05), but still lower than that in healthy people(P<0.05); the levels of serum PDGF-BB in patients with hepatitis B cirrhosis before and after treatment were significantly lower than those in healthy people(P<0.01), and increased after treatment, but the increase was not statistically significant(P>0.05);compared with before treatment, there was significant difference in the improvement of liver function(P<0.01). Conclusion The changes of PDGF-AB and PDGF-BB levels are related to the occurrence of post-hepatitis B cirrhosis. Yiqi Jiedu Tongluo granules can improve the serum levels of PDGF-AB and PDGF-BB in patients with hepatitis B cirrhosis, especially on PDGF-AB.
引文
[1]王宏利,田艳红,阚洪敏,等.Fibroscan与乙型肝炎肝硬化患者门脉高压性胃病相关性研究[J].陕西医学杂志,2015,44(3):327-329.
[2]董增辉,李慧瑛,吕婷.还原性谷胱甘肽联合核苷类似物治疗乙肝肝硬化临床研究[J].陕西医学杂志,2018,47(4):527-529.
[3]Wang XB,Liu P,Tang ZP.Intervening and therapeutic effect of cordyceps mycelia extract on liver cirrhosis induced by dimethylnitrosamine in rats[J].Zhongguo Zhong Xi Yi Jie He Za Zhi,2008,28(7):617-622.
[4]Balsano C,Alisi A,Nobili V.Liver fibrosis and therapeutic strategies:the goal for improving metabolism[J].Curr Drug Targets,2009,10(6):505-512.
[5]Domitrovic R,Jakovac H.Antifibrotic activity of anthocyanidin delphinidin in carbon tetrachloride-induced hepatotoxicity in mice[J].Toxicology,2010,272(1-3):1-10.
[6]Rodriguez C,Romero-Trevejo JL,Gondi G,et al.Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats[J].Hepatology,2010,51(3):912-921.
[7]Andrae J,Gallini R,Betsholtz C.Role of platelet-derived growth factors in physiology and medicine[J].Genes Dev,2008,22(10):1276-1312.
[8]方玉强.血小板衍生生长因子在组织细胞再生和创伤修复的作用及其机制[J].国外医学创伤与外科基本问题分册,1997,18(1):1-3.
[9]中国中西医结合学会消化系统疾病专业委员会.肝硬化临床诊断、中医辨证和疗效评定标准(试行方案)[A].中华中医药学会全国第十一届中医肝胆病学术会论文集[C].北京:中华中医药学会,2006:215-216.
[10]梁扩寰.肝脏病学[M].北京:人民卫生出版社,2006:87.
[11]中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].中华肝脏病杂志,2011,19(1):13-24.
[12]段成颖.恩替卡韦联合自拟方剂治疗乙肝肝硬化的效果[J].光明中医,2017,32(8):1172-1174.
[13]赫伟丽,徐光福,王宁,等.恩替卡韦联合益气解毒通络方治疗乙型肝炎肝硬化代偿期的临床观察[J].中医临床研究,2015,11(10):1-2.
[14]庄灿皇.基于近二十年文献中医药治疗肝纤维化的方药规律研究[D].广州:广州中医药大学,2016.
[2]董增辉,李慧瑛,吕婷.还原性谷胱甘肽联合核苷类似物治疗乙肝肝硬化临床研究[J].陕西医学杂志,2018,47(4):527-529.
[3]Wang XB,Liu P,Tang ZP.Intervening and therapeutic effect of cordyceps mycelia extract on liver cirrhosis induced by dimethylnitrosamine in rats[J].Zhongguo Zhong Xi Yi Jie He Za Zhi,2008,28(7):617-622.
[4]Balsano C,Alisi A,Nobili V.Liver fibrosis and therapeutic strategies:the goal for improving metabolism[J].Curr Drug Targets,2009,10(6):505-512.
[5]Domitrovic R,Jakovac H.Antifibrotic activity of anthocyanidin delphinidin in carbon tetrachloride-induced hepatotoxicity in mice[J].Toxicology,2010,272(1-3):1-10.
[6]Rodriguez C,Romero-Trevejo JL,Gondi G,et al.Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats[J].Hepatology,2010,51(3):912-921.
[7]Andrae J,Gallini R,Betsholtz C.Role of platelet-derived growth factors in physiology and medicine[J].Genes Dev,2008,22(10):1276-1312.
[8]方玉强.血小板衍生生长因子在组织细胞再生和创伤修复的作用及其机制[J].国外医学创伤与外科基本问题分册,1997,18(1):1-3.
[9]中国中西医结合学会消化系统疾病专业委员会.肝硬化临床诊断、中医辨证和疗效评定标准(试行方案)[A].中华中医药学会全国第十一届中医肝胆病学术会论文集[C].北京:中华中医药学会,2006:215-216.
[10]梁扩寰.肝脏病学[M].北京:人民卫生出版社,2006:87.
[11]中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].中华肝脏病杂志,2011,19(1):13-24.
[12]段成颖.恩替卡韦联合自拟方剂治疗乙肝肝硬化的效果[J].光明中医,2017,32(8):1172-1174.
[13]赫伟丽,徐光福,王宁,等.恩替卡韦联合益气解毒通络方治疗乙型肝炎肝硬化代偿期的临床观察[J].中医临床研究,2015,11(10):1-2.
[14]庄灿皇.基于近二十年文献中医药治疗肝纤维化的方药规律研究[D].广州:广州中医药大学,2016.